ResMed FY2026: revenue up 10% to $5.65 billion, non-GAAP EPS up 17%
ResMed closed fiscal 2026 with 10.0% revenue growth to $5.65 billion and a 17.0% rise in non-GAAP earnings per share, so the core sleep and breathing franchise is compounding while margins widen. The fourth quarter looks messier on the GAAP line because $41.9 million of Astral field safety notification expenses landed in cost of sales. Read the quarter through non-GAAP gross margin, which still rose to 62.3%.
1 · Expected vs. Actual
Free preview belowGAAP diluted EPS was $10.43 for the year, up 10.0%, while non-GAAP diluted EPS rose 17.0% to $11.17. The fourth quarter shows the split clearly: GAAP EPS of $2.64 rose just 2.0% because of the $41.9 million Astral charge, while non-GAAP EPS of $2.95 rose 16.0% and sat slightly above the $2.9183 consensus estimate. Which basis that consensus uses is not stated, and $2.64 would sit below it.
Full-year revenue reached $5.65 billion, up 10.0% as reported and 8.0% in constant currency (the release rounds this to $5.7 billion). The fourth quarter contributed $1.46 billion, up 9.0%, split across Devices at $0.75 billion, Masks and other at $0.54 billion and Residential Care Software at $0.17 billion. Growth was broad, but the software piece — the business ResMed has agreed to sell — managed only 2.0% in constant currency.
Log in to read 5 analyses a week for free
Create a free account to read 5 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.